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DORES, R. M. AND H. AKIL. Steady state levels of pro-dynorphin-related end products in the striatum and substantia 
nigra of the adult rhesus monkey. PEPTIDES 6: Suppl. 2, 143-148, 1985.-Analysis of an acid extract of the striatum of the 
rhesus monkey revealed that the molar ratio of dynorphin A(1-8)-sized material and dynorphin (A(1-17)-sized material is 
approximately I:1. In addition, the molar ratios of the dynorphin A-related end products to both dynorphin B(l-13)-sized 
material and alpha-neo-endorphin-sized material were approximately 1:1. Fractionation of an acid extract of the substantia 
nigra by gel filtration and reverse phase HPLC revealed the following molar ratios for pro-dynorphin-related end products. 
The molar ratio of dynorphin A(1-8) to dynorphin A(1-17) is approximately 6:1. The molar ratios of dynorphin A-related 
end products to dynorphin B(1-13) and alpha-neo-endorphin were approximately 0.5 and 0.8, respectively. Comparisons 
between proteolytic processing patterns of pro-dynorphin in the striatum and the substantia nigra of the rhesus monkey are 
considered. In addition, comparisons between pro-dynorphin processing in the substantia nigra of the rhesus monkey and 
the substantia nigra of the rat [4] are discussed. 
Pro-dynorphin Striatum Substantia nigra Processing 
SEQUENCES of  the opioid peptides, alpha-neo-endorphin 
I1 l l, d ynorphin A(1-17) [7], and dynorphin B(1-13) [5,14] are 
all contained within the sequence of the polyprotein,  pro- 
dynorphin [10]. Differential proteolytic processing of this 
precursor at sites of  either paired basic amino acids (i.e., 
Lys-Arg) or at a single Arg residue can give rise to a variety 
of  opioid end products.  In addition to the peptides listed 
above,  the following opioid peptides have also been detected 
in pro-dynorphin systems: beta-neo-endorphin [18], dynor- 
phin A( l -8)  [17,24] and leumorphin ([19,35]; the COOH- 
terminal extended form of dynorphin B(l-13)). 
Several anatomical studies on the distribution of pro- 
dynorphin-related end products in the brain of the rat indi- 
cate that there is not just  a single pro-dynorphin circuit in the 
central nervous system, but rather several independent pro- 
dynorphin networks which are distributed widely throughout 
the brain [12, 16, 26, 27, 28, 29, 30, 31]. Accordingly,  studies 
on the steady state levels of  pro-dynorphin-related end prod- 
ucts in the central nervous system of the rat [2, 25, 32] indi- 
cate that pro-dynorphin can undergo differential post- 
translational processing to yield distinct sets of end products 
in different regions of the rat brain. However ,  because of the 
complex anatomical distribution of pro-dynorphin perikarya 
and terminals in the central nervous system, it is necessary 
to go beyond regional analysis and focus on anatomically 
well defined pro-dynorphin networks. This study will con- 
sider processing of pro-dynorphin in the striato-nigral path- 
way. 
Anatomical studies on the brain of the rat have clearly 
established that pro-dynorphin perikarya can be localized in 
the caudate-putamen (i.e., striatum; [12, 29, 30]). Independ- 
ently, two groups have demonstrated by chemical lesion [26] 
and surgical lesion [34] experiments that pro-dynorphin 
perikarya located in the striatum project to the substantia 
nigra. A comparison of  the steady state levels of  dynorphin 
A-related material in the substantia nigra and the posterior 
pituitary, the terminal field for magnocellular neurons 
originating in the supraoptic and paraventricular nuclei [27, 
28, 31], revealed that the molar ratio of dynorphin A(1-8) to 
dynorphin A(l-17)  in the posterior pituitary is approximately 
l: l ,  whereas the molar ratio of these peptides in the substan- 
tia nigra is approximately 16: l [4]. Thus, the proteolytic pro- 
cessing events that occur in the rat striato-nigral pathway 
result in the conversion of dynorphin A(l-17) ,  a highly 
selective kappa agonist, to dynorphin A(l -8) ,  an opioid with 
mixed selectively for kappa and delta receptors [1, 3, 20, 22, 
23, 33]. Since pro-dynorphin is differentially processed in 
two anatomically distinct systems within the rat brain, the 
present study was done to determine whether similar pro- 
cessing patterns for pro-dynorphin could be observed in the 
substantia nigra of a primate, the rhesus monkey. 
~Send reprint requests to R. M. Dores, University of Denver, Department of Biological Sciences, Denver, CO 80208. 
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METHOD 
For  these experiments the striatum (wet weight: 4.8 g) 
and the substantia nigra (wet weight: 0.6 g) were collected 
from an adult postmenopausal  female rhesus monkey (spe- 
cies: Macaque mulatta), obtained from the Primate Re- 
search Center at the University of Michigan School of 
Medicine. The tissues were separately extracted in ten vol- 
umes of  acetone:0. I N HCI (3: I). The homogenate was cen- 
trifuged for 45 min at 12,000 rpm, and the supernatant was 
concentrated under vacuum (Savant Speed Vac). The dried 
extract was dissolved in a volume of  10% formic acid and 
fractionated by gel filtration on a Sephadex G-50 superfine 
column (Pharmacia) equilibrated in 10% formic acid which 
contained 100 tzg/ml bovine serum albumin. Following gel 
filtration, aliquots of  the column fractions were concentrated 
under vacuum and analyzed by radioimmunoassay.  The re- 
covery of  immunoreactivity following gel filtration averaged 
85%. 
Radioimmunoassays for dynorphin A(1-17), dynorphin 
A(1-8), dynorphin B(1-13), and alpha-neo-endorphin were 
done following the method described by Ghazarossian et al. 
[6] with some modifications. All primary antisera were raised 
in rabbits as described by Khachaturian et al. [12]. Synthetic 
dynorphin A(1-17), dynorphin A(I-8) ,  and alpha-neo- 
endorphin were purchased from Bachem (Torrance, CA). 
Synthetic dynorphin B(1-13) was provided by Dr. Richard 
Houghton (Scripps Institute). Peptides were iodinated by the 
chloramine T procedure.  For  dynorphin A(1-17) and dynor- 
phin A(1-8) assays the RIA buffer consisted of  methanol/0.1 
N HCI (3:11 and 150 mM sodium phosphate,  0.1% bovine 
serum albumin, 0. l% triton X-100, pH 8.2 buffer in a ratio of 
1:2.5. For  dynorphin B(1-13) and alpha-neo-endorphin as- 
says, the RIA buffer consisted of  methanol/0.1 N HCI (3:1) 
and 150 mM sodium phosphate,  1% bovine serum albumin, 
0.1% triton X-100, pH 7.5 buffer, in a ratio of  1:2.5. For  all 
RIAs, the final reaction volume was 200 ~zl. RIAs were run at 
4°C for 18-24 hr and terminated by the double antibody pro- 
cedure using goat anti-rabbit IgG. The primary antisera used 
in these assays had the following specificities. 
Dynorphin A( I-17) 
Antisera No. 54 (final concentration: 1:12,000) was raised 
against synthetic dynorphin A(I-17).  This antisera has 80% 
molar crossreactivity with dynorphin A(1-13), but less than 
0.1% molar crossreactivity with dynorphin A(1-8), dynor- 
phin B(1-13), alpha-neo-endorphin and leucine enkephalin. 
This antisera crossreacts in a parallel manner with 11K, 6K, 
and 4K forms of dynorphin A-related immunoreactivity [4]. 
The midpoint of this assay is 70 fmol/tube. 
Dynorphin A( I--8) 
Antisera No. 73 (final concentration: 1:5,000) was raised 
against synthetic dynorphin A(1-8). This antisera has I% 
molar crossreactivity with dynorphin A(1-17) and less than 
0.1% molar crossreactivity with alpha-neo-endorphin, 
dynorphin B(1-13) and leucine enkephalin. This antisera 
does not appear  to crossreact  with high molecular weight 
forms of dynorphin A. The midpoint of this assay is 90 
fmol/tube. 
Dynorphin B( I-13) 
Antisera No. 94 (final concentration: 1:4,000) was raised 
against synthetic dynorphin B(1-13). This antisera has less 
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FIG. I. Gel filtration of an acid extract of the striatum of the rhesus 
monkey. An acid extract of 0.5 equivalents of striatum (wet weight: 
2.6 g) was fractionated by gel filtration on a Sephadex G-50 super- 
fine column (1.5x70 cm) equilibrated in 10% formic acid/0.1% 
bovine serum albumin. The flow rat was 1.5 ml/hr and I ml fractions 
were collected. The V,, was marked with bovine serum albumin and 
the Vt was marked with 2,mercaptoethanol both detected spec- 
trophotometrically at A._,m,. Aliquots of fractions were concentrated 
and analyzed by radioimmunoassay. (A) Profile of dynorphin A(I- 
17)-related immunoreactivity (O--II) and dynorphin A(I-8)-related 
immunoreactivity (O (~). (B) Profile of dynorphin B-related im- 
munoreactivity (0 - -0 )  and alpha-neo-endorphin-related im- 
munoreactivity (© 0). The following standards were used to cali- 
brate this column: (I) synthetic ACTHll-391; (21 synthetic human 
beta-endorphin(l-31); (3) synthetic porcine dynorphin A(1-171; (4) 
synthetic porcine dynorphin A(1-8). 
than 0.1% molar crossreactivity with dynorphin A(I-17),  
dynorphin A(I-81. alpha-neo-endorphin or leucine en- 
kephalin. However,  this antisera does crossreact in a par- 
allel manner with 6K and 4K forms of dynorphin B-related 
material. The midpoint of this assay is 60 fmol/tube. 
A Ipha-Neo-Endorphin 
Antisera No. 59 (final concentration: 1:4,000) was raised 
against synthetic alpha-neo-endorphin. This antisera has 1% 
molar crossreactivity with beta-neo-endorphin, and less than 
0.1% molar crossreactivity with dynorphin A(I-17),  dynor- 
phin A(1-8), alpha-neo-endorphin or leucine enkephalin. 
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TABLE I 
Peptide pmol/g Tissue 
Striatum 
Dynorphin A (1-17) 10 
Dynorphin A (1-8) 12 
Dynorphin B (1-13) 21 
Alpha-neo-endorphin 18 
Substantia Nigra 
Dynorphin A (1-17) 12 
Dynorphin A (1-8) 74 
Dynorphin B (1-13) 45 
Alpha-neo-endorphin 69 
This antisera does not appear  to crossreact  with any high 
molecular weight forms of alpha-neo-endorphin-related 
material. The midpoint of this assay is 70 fmol/tube. 
Peaks of immunoreactivity isolated by gel filtration were 
separately analyzed by reverse phase high performance liq- 
uid chromatography (HPLC) on a Beckman ODS ultrasphere 
5 micron column (4.6 mm×25 cm). The column was eluted 
with a 4 to 32% nonlinear gradient of acetonitrile in 0.1% 
trifluoacetic acid (Pierce). The recovery of immunoreactivity 
from this column averaged 80%. 
R E S U L T S  
Steady State Levels of Pro-Dym)rphin-Related Products in 
the Striatum 
Anatomical and biochemical analyses of the striato-nigral 
pro-dynorphin network have primarily focused on the rat 
system [4, 12, 26, 34]. Anatomical studies of the rhesus mon- 
key central nervous system indicate that pro-dynorphin 
perikarya can also be demonstrated in the caudate nucleus of  
this species [13]. In addition, pro-dynorphin-related im- 
munoreactivity is primarily concentrated in the zona re- 
ticulata of the substantia nigra of this species with a distribu- 
tion similar to what has already been reported for the rat 
substantia nigra [12]. The apparent similarities between the 
well defined striato-nigral pro-dynorphin pathway in the rat 
and the apparent striato-nigral pathway in the rhesus mon- 
key prompted us to compare the steady state levels of pro- 
dynorphin products in the striatum (caudate and putamen) 
and substantia nigra of  the rhesus monkey. Furthermore,  
additional studies on the processing of  pro-dynorphin in the 
brain of a primate are of interest, given the observation that 
the concentration of pro-dynorphin-related products in the 
human substantia nigra is particularly high relative to other 
regions of the brain [15]. 
Analysis of  an extract  of the striatum of the rhesus mon- 
key by gel filtration chromatography in conjunction with 
radioimmunoassay analyses is shown in Fig. 1. Four  peaks 
of dynorphin A-related material were detected in this extract 
(Fig. 1A). The dynorphin A(1-17) RIA detected two minor 
peaks (K,,.=0.30 and 0.43, respectively) and one major peak 
(K, ,=0.67) .  The minor peaks have apparent molecular 
weights of approximately 6K and 4K, respectively,  and are 
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FIG. 2. Gel fi ltration of an acid extract of the substantia nigra of the 
rhesus monkey. An acid extract of 0.5 equivalents of substantia 
nigra (wet weight: 0.3 g) was fractionated by gel fi ltration on a 
Sephadex G-50 superfine column (lx50 cm) equilibrated in 10% 
formic acid/0.1% bovine serum albumin as described in the legend to 
Fig. 1. The fraction size was 0.4 ml. CA) Profile of dynorphin A(1- 
17)-related immunoreactivity (O O) and dynorphin (A(1-8)-related 
immunoreactivity (©--O). (B) Profile of dynorphin B-related im- 
munoreactivity (0 - -0 )  and alpha-neo-endorphin-related im- 
munoreactivity (©--©). The standards used to calibrate this column 
were: CA) cytochrome C; (B) synthetic porcine ACTH(I-39); (C)) 
synthetic human beta-endorphin(l-31); (D) synthetic porcine 
dynorphin A(I-17); (E) synthetic porcine dynorphin B(1-13); (F) 
synthetic porcine dynorphin A(1-8); (G) synthetic leucine 
enkephalin. 
from extracts of rat posterior pituitary [4]. The major peak of 
dynorphin A(1-17)-related immunoreactivity eluted at the 
same position as synthetic porcine dynorphin A(1-17). The 
dynorphin A(1-8) RIA detected a single peak of im- 
munoreactivity (K,v=0.86) with the same apparent molecu- 
lar weight as synthetic porcine dynorphin A(1-8). In this 
tissue the molar ratio of dynorphin A(l-8)-s ized material to 
dynorphin A(I-17) is approximately 1:1 (Table 1). These re- 
sults are in contrast  to analyses of the rat striatum where the 
levels of dynorphin A(1-8)-sized material range from 9 to 16 
fold higher than the dynorphin A(I-17)-sized material 
([25,32]; Dores, unpublished data). 
The dynorphin B(1-13) RIA also detected multiple peaks 
of immunoreactivity (Fig. IB). Two minor peaks of  im- 
munoreactivity (K, ,=0 .28  and 0.44) correspond to material 
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with apparent molecular weights of 6K and 4K, respectively. 
The major peak of immunoreactivity (Kay=0.74) has the 
same apparent molecular weight as synthetic porcine dynor- 
phin B(1-13). In this tissue the molar ratio of dynorphin 
B(l-13)-sized material to dynorphin A (dynorphin A(I-8)-  + 
dynorphin A(1-17)-sized material) is approximately 1:1. The 
alpha-neo-endorphin RIA detected a single peak of im- 
munoreactivity (K,~v=0.77) and this peak has the same ap- 
parent molecular weight as synthetic porcine alpha-neo- 
endorphin (Fig. 1B). The alpha-neo-endorphin-sized material 
is also present in roughly equimolar amounts with the dynor- 
phin A-related material (Table 1). 
Steady State Levels of  Pro-Dynorphin-Related End Products 
in the Substantia Nigra 
The preceding section dealt with a consideration of the 
pro-dynorphin-related products in the striatum (Fig. 1 and 
Table 1). Although the striatum contains pro-dynorphin 
perikarya which are presumed to project to the substantia 
nigra, it is clear from anatomical studies on both the rat [12] 
and rhesus monkey [13] striatum that this region of  the brain 
not only contains perikarya,  but also contains fibers of pas- 
sage as well as local terminal fields. By contrast,  the sub- 
stantia nigra is devoid of  pro-dynorphin perikarya and con- 
'ains only terminal fields, thus the forms of pro-dynorphin- 
' lated end products detected in this area represent the final 
~cessed forms which are presumably being stored for se- 
cretion. 
Analysis of an extract  of the substantia nigra of the rhesus 
monkey are presented in Figs. 2 and 3 and Table 1. Gel 
filtration of this extract (Fig. 2A) followed by analysis with 
the dynorphin A(I-17) RIA detected two minor peaks of 
dynorphin A-related immunoreactivity (K,,  =0.45 and 0.67). 
The former peak eluted with an apparent molecular weight of 
4K and the latter peak has the same apparent  molecular 
weight as synthetic porcine dynorphin A(1-17). The major 
peak of dynorphin A-related material in this extract was de- 
tected with the dynorphin A(1-8) RIA. This peak of im- 
munoreactivity (Kav=0.85) has the same apparent molecular 
weight as synthetic dynorphin A(1-8). The identities of  the 
dynorphin A(1-17)-sized material and the dynorphin A(1- 
8)-sized material isolated in Fig. 2A were confirmed by re- 
verse phase HPLC analysis (Fig. 3B). The molar ratios of 
these dynorphin A-related end products are summarized in 
Table 1. In the rhesus monkey substantia nigra the molar 
ratio of dynorphin A(1-8) to dynorphin A(1-17) is approx- 
imately 6: 1. 
Analysis of the extract of  the substantia nigra with the 
dynorphin B(1-13) RIA also revealed multiple peaks of im- 
munoreact ivi ty  (Fig. 2B). Two minor peaks (K~,v=0.31 and 
0.45) and a major peak (Kay=0.73) were detected.  The lat- 
ter peak has the same apparent  molecular  weight as syn- 
thetic dynorphin B(1-13). Analysis  of  this peak of im- 
munoreact ivi ty  by reverse phase HPLC (Fig. 3A) indi- 
cated that the dynorphin B(1-13)-sized material  migrated 
with the same retention time as synthetic porcine dynorphin 
B(!-13). The molar ratio of  dynorphin B(1-13) to dynorphin 
A(dynorphin A(1-17) + dynorphin A(1-8)) is approximate 
0.5:1 (Table 1). 
Analysis of  the extract  of  the substantia nigra with the 
alpha-neo-endorphin RIA (Fig. 2B) revealed a single peak of 
immunoreactive material (K,v=0.77) with the same apparent 
molecular weight as synthetic porcine alpha-neo-endorphin. 



















E 1.0 o_ 
O5 
DYN B 
20 25 30 
Retentaon Time (Min) 








8 2  
1"0 15 20 25 30 
Retention Time (Min) 
FIG. 3. HPLC profiles of dynorphin A(1-17), dynorphin A(I-8), 
dynorphin B(I-13) and alpha-neo-endorphin isolated from the sub- 
stantia nigra of the rhesus monkey. Reverse phase HPLC analysis of 
purified pro-dynorphin-related end products was done on a 
Beckman ODS ultrasphere 5 micron column as described in the 
Method section. (A) Aliquots (0.25 ml) of fractions No. 47-53 from 
Fig. 2 were pooled and concentrated. The concentrate was redissol- 
ved in 0.08 ml of 0.1% trifluoacetic acid and applied to the column. 
The fraction size was 1 ml and 0.5 ml aliquots were analyzed with 
both the dynorphin B(I-13) RIA and the alpha-neo-endorphin RIA. 
(B) Aliquots (0.3 ml) from fractions No. 52-55 from Fig. 2 were 
pooled and concentrated for HPLC analysis. The fraction size was 1 
ml and 0.5 ml aliquots were analyzed with the dynorphin A(I-8) 
RIA. In a separate chromatogram, aliquots (0.25 ml) of fractions No. 
44-47 from Fig. 2 were pooled and concentrated for HPLC analysis. 
The fraction size was 1 ml and 0.5 ml aliquots were analyzed with 
the dynorphin A(1-17) RIA. For convenience, the dynorphin A(1-8) 
and the dynorphin A(I-17) chromatograms were drawn together. 
The following synthetic standards were run separately and the re- 
tention times are marked with an arrow: alpha-neo-endorphin, 
dynorphin B(I- 13), dynorphin A(1-8) and dynorphin A( 1-17). 
HPLC analysis (Fig. 3A). The molar ratio of alpha-neo- 
endorphin to dynorphin A in this tissue is approximately 
0.8:1. 
D I S C U S S I O N  
The action of opiates on the nigro-striatal dopaminergic 
pathway is a very complex issue (for review see [21]). A 
recent study indicates that administration of  opioid peptides 
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at the level of the zona reticulata of  the substantia nigra 
appears to influence the activity of  the dopaminergic 
per ikarya in the zona compacta  of  the substantia nigra [8]. 
Accordingly,  anatomical studies of the zona reticulata of  the 
rat and rhesus monkey brain [12,13] indicate that this region 
of the substantia nigra contains an extensive pro-dynorphin 
terminal field. Lesion studies have established that in the rat 
brain pro-dynorphin per ikarya originating in the striatum 
project to the substantia nigra [26,34]. Although it appears 
that the major pro-dynorphin projection to the substantia 
nigra comes from the striatum, the possibility of extra- 
striatai projections can not be eliminated at this time. With 
the detection of pro-dynorphin perikarya in the striatum of 
the rhesus monkey and the extensive pro-dynorphin terminal 
field in the substantia nigra of this species, it appears highly 
likely that a pro-dynorphin striato-nigral network is also 
present in the rhesus monkey. 
In the present study we examined the steady state levels 
of pro-dynorphin-related products in the striatum and sub- 
stantia nigra of the rhesus monkey. Both regions of the 
rhesus monkey brain contain dynorphin A(1-17)-, dynorphin 
A(I-8)- ,  dynorphin B(I-13)-, and alpha-neo-endorphin-sized 
material which appear  to be chromatographically identical to 
the porcine forms of these pro-dynorphin opioid end prod- 
ucts. Sequence analysis of the pro-dynorphin gene obtained 
from a human genomic DNA library [9] indicates that in this 
primate the opioid peptide sequences are identical to the 
porcine sequences [10]. Thus in mammals as diverse as ro- 
dent. porcine and primate the opioid sequences of pro- 
dynorphin are highly conserved. 
In the striatum of  the rhesus monkey roughly equimolar 
amounts of  dynorphin A (dynorphin A(1-17) + dynorphin 
A(1-8)), dynorphin B(I-13),  and alpha-neo-endorphin were 
detected. One of the striking features of the rhesus monkey 
striatum is the roughly equimolar amounts of  dynorphin 
A( 1-17)- and dynorphin A(1-8)-sized material. This is in con- 
trast to the striatum of the rat where the predominant form of 
dynorphin A is dynorphin A(I-8)  [25,32]. Furthermore,  al- 
though high molecular weight forms of dynorphin A-related 
material and dynorphin B-related material were detected,  the 
predominant forms of pro-dynorphin products in the 
striatum were the low molecular opioid peptides. 
In the substantia nigra of the rhesus monkey proteolytic 
processing of pro-dynorphin has proceeded even further 
than in the striatum. Although high molecular weight forms 
of dynorphin A-related and dynorphin B-related material 
were detected in the substantia nigra, these forms were pres- 
ent in a lower percentage than in the striatum. These data 
suggest that proteolytic processing proceeds to near com- 
pletion in the substantia nigra. Further  evidence of  the extent 
of  proteolytic processing in the substantia nigra is seen in the 
molar ratio of dynorphin A(1-17) and dynorphin A(1-8). In 
the striatum these forms were present in roughtly a 1:1 ratio, 
whereas in the substantia nigra there is 6 fold more dynor- 
phin A(1-8) as compared to dynorphin A(1-17). The increase 
in the levels of  dynorphin A(1-8) in the substantia nigra as 
compared to the striatum and the accompanying shift in 
opiate receptor specificity of  dynorphin A(1-8) may have 
functional significance. It is noteworthy,  however,  that the 
ratio of  the forms of dynorphin A in the rhesus monkey 
substantia nigra is not as extreme as the ratio of  these forms 
in the rat substantia nigra, where there is approximately 16 
fold more dynorphin A(1-8) as compared to dynorphin A(1- 
17) [4]. 
Another difference between the steady state levels of 
pro-dynorphin products in the striatum and substantia nigra 
of  the rhesus monkey is that the molar ratio of dynorphin A, 
dynorphin B(1-13), and alpha-neo-endorphin were approx- 
imately 1:1 in the striatum, however,  in the substantia nigra 
there were approximately 20% and 50% less of  alpha-neo- 
endorphin and dynorphin B(1-13), respectively,  as com- 
pared to dynorphin A end products. The minor drop in 
alpha-neo-endorphin may indicate a conversion to beta- 
neo-endorphin. The 50% drop in dynorphin B(1-13) relative 
to dynorphin A end products may reflect a conversion of the 
former to leucine enkephalin. The use of  a biosynthetic 
labelling paradigm will be required in order to properly eval- 
uate these possibilities. 
Finally, the results reported in this study reflect the 
steady state levels of  pro-dynorphin products in the adult 
female rhesus monkey. Further  studies are needed on 
animals of both sexes at different periods in ontogeny in 
order to obtain a better  understanding of  pro-dynorphin pro- 
cessing in primates. 
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